SG Americas Securities LLC Has $5.27 Million Position in Haleon PLC Sponsored ADR $HLN

SG Americas Securities LLC boosted its stake in Haleon PLC Sponsored ADR (NYSE:HLN) by 1,721.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 521,539 shares of the company’s stock after purchasing an additional 492,910 shares during the quarter. SG Americas Securities LLC’s holdings in Haleon were worth $5,273,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of HLN. SOA Wealth Advisors LLC. raised its holdings in shares of Haleon by 60.5% during the third quarter. SOA Wealth Advisors LLC. now owns 3,105 shares of the company’s stock valued at $28,000 after purchasing an additional 1,170 shares during the period. Citizens National Bank Trust Department increased its position in Haleon by 167.4% in the 3rd quarter. Citizens National Bank Trust Department now owns 3,276 shares of the company’s stock valued at $29,000 after buying an additional 2,051 shares in the last quarter. Atlantic Union Bankshares Corp increased its position in Haleon by 293.7% in the 3rd quarter. Atlantic Union Bankshares Corp now owns 3,697 shares of the company’s stock valued at $33,000 after buying an additional 2,758 shares in the last quarter. Stance Capital LLC acquired a new position in Haleon during the 3rd quarter worth approximately $34,000. Finally, Geneos Wealth Management Inc. boosted its holdings in Haleon by 33.0% in the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after acquiring an additional 1,203 shares in the last quarter. 6.67% of the stock is owned by institutional investors.

Haleon Stock Performance

Shares of HLN opened at $9.97 on Thursday. The firm has a market capitalization of $44.37 billion, a P/E ratio of 25.55 and a beta of 0.26. Haleon PLC Sponsored ADR has a 52 week low of $8.71 and a 52 week high of $11.42. The stock has a 50 day moving average price of $10.52 and a two-hundred day moving average price of $9.88. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.71 and a current ratio of 0.92.

Haleon Announces Dividend

The business also recently declared a dividend, which will be paid on Thursday, May 14th. Investors of record on Friday, April 10th will be given a $0.1307 dividend. This represents a yield of 251.0%. The ex-dividend date of this dividend is Friday, April 10th. Haleon’s dividend payout ratio is presently 28.21%.

Analysts Set New Price Targets

HLN has been the subject of a number of research reports. HSBC raised Haleon from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, January 21st. Argus upgraded Haleon to a “strong-buy” rating in a report on Tuesday, March 17th. Deutsche Bank Aktiengesellschaft downgraded shares of Haleon from a “hold” rating to a “sell” rating in a research report on Monday, January 12th. Morgan Stanley restated an “overweight” rating on shares of Haleon in a report on Monday, December 15th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Haleon has a consensus rating of “Moderate Buy” and a consensus price target of $12.33.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.